You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Olmesartan Medoxomil And Hydrochlorothiazide, and when can generic versions of Olmesartan Medoxomil And Hydrochlorothiazide launch?

Olmesartan Medoxomil And Hydrochlorothiazide is a drug marketed by Accord Hlthcare, Alembic, Aurobindo Pharma, Macleods Pharms Ltd, Natco Pharma Usa, Prinston Inc, Teva Pharms Usa, Torrent, Umedica, and Zydus Pharms. and is included in ten NDAs.

The generic ingredient in OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; olmesartan medoxomil. There are thirty-two drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; olmesartan medoxomil profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Olmesartan Medoxomil And Hydrochlorothiazide

A generic version of OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE was approved as hydrochlorothiazide; olmesartan medoxomil by ALKEM LABS LTD on July 11th, 2024.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE?
  • What are the global sales for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE?
  • What is Average Wholesale Price for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE?
Summary for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
US Patents:0
Applicants:10
NDAs:10
Finished Product Suppliers / Packagers: 10
Clinical Trials: 26
What excipients (inactive ingredients) are in OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE?OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE excipients list
DailyMed Link:OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE at DailyMed
Drug patent expirations by year for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Recent Clinical Trials for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Altasciences Company, Inc.Phase 1
Altasciences Company Inc.Phase 1
Pharmtechnology LLCPhase 1

See all OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE clinical trials

Pharmacology for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

US Patents and Regulatory Information for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 206377-001 Feb 24, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 206377-002 Feb 24, 2023 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Accord Hlthcare OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 209281-001 Feb 7, 2019 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Prinston Inc OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 207804-003 Apr 24, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Torrent OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 206515-003 May 3, 2017 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 205391-001 Apr 24, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.